Tegsedi
Familial Amyloid Polyneuropathy
Akcea TherapeuticsPhase 4 / ApprovedActive
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 55/ 100
- Competitive Position
- 95/ 100
Competitive context
9 Active assets in the Familial Amyloid Polyneuropathy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
fx-1006a Qilu Pharmaceutical Co., Ltd. | Phase 4 | A |
fx-1006a Pfizer | Phase 4 | BBB |
Revusiran Alnylam Pharmaceuticals | Phase 3 | BB |
fx-1006a Qilu Pharmaceutical Co., Ltd. | Phase 4 | BB |
Patisiran Alnylam Pharmaceuticals | Phase 3 | BB |
View all 18 →
Same molecule, other indications
Tegsedi is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →